The findings of this study not only explored the correlation between abnormal LCFA metabolism and the key pathogenic factor IL-17A in psoriasis patients but also provided a theoretical foundation for the use of anti-IL-17A mAb in treating the skin lesions of psoriasis patients while improving their abnormal LCFA metabolism. Here, IL17A is linked to psoriasis.